TY - JOUR
T1 - Genetic Screening-Emerging Issues
AU - Cornel, Martina C
AU - van der Meij, Karuna R M
AU - van El, Carla G
AU - Rigter, Tessel
AU - Henneman, Lidewij
N1 - Publisher Copyright: © 2024 by the authors.
PY - 2024/5/3
Y1 - 2024/5/3
N2 - In many countries, some form of genetic screening is offered to all or part of the population, either in the form of well-organized screening programs or in a less formalized way. Screening can be offered at different phases of life, such as preconception, prenatal, neonatal and later in life. Screening should only be offered if the advantages outweigh the disadvantages. Technical innovations in testing and treatment are driving changes in the field of prenatal and neonatal screening, where many jurisdictions have organized population-based screening programs. As a result, a greater number and wider range of conditions are being added to the programs, which can benefit couples' reproductive autonomy (preconception and prenatal screening) and improve early diagnosis to prevent irreversible health damage in children (neonatal screening) and in adults (cancer and cascade screening). While many developments in screening are technology-driven, citizens may also express a demand for innovation in screening, as was the case with non-invasive prenatal testing. Relatively new emerging issues for genetic screening, especially if testing is performed using DNA sequencing, relate to organization, data storage and interpretation, benefit-harm ratio and distributive justice, information provision and follow-up, all connected to acceptability in current healthcare systems.
AB - In many countries, some form of genetic screening is offered to all or part of the population, either in the form of well-organized screening programs or in a less formalized way. Screening can be offered at different phases of life, such as preconception, prenatal, neonatal and later in life. Screening should only be offered if the advantages outweigh the disadvantages. Technical innovations in testing and treatment are driving changes in the field of prenatal and neonatal screening, where many jurisdictions have organized population-based screening programs. As a result, a greater number and wider range of conditions are being added to the programs, which can benefit couples' reproductive autonomy (preconception and prenatal screening) and improve early diagnosis to prevent irreversible health damage in children (neonatal screening) and in adults (cancer and cascade screening). While many developments in screening are technology-driven, citizens may also express a demand for innovation in screening, as was the case with non-invasive prenatal testing. Relatively new emerging issues for genetic screening, especially if testing is performed using DNA sequencing, relate to organization, data storage and interpretation, benefit-harm ratio and distributive justice, information provision and follow-up, all connected to acceptability in current healthcare systems.
KW - DNA sequencing
KW - cascade screening
KW - genetic carrier screening
KW - genetic screening
KW - neonatal screening
KW - prenatal screening
KW - screening criteria
UR - http://www.scopus.com/inward/record.url?scp=85194219753&partnerID=8YFLogxK
U2 - 10.3390/genes15050581
DO - 10.3390/genes15050581
M3 - Review article
C2 - 38790210
SN - 2073-4425
VL - 15
JO - Genes
JF - Genes
IS - 5
M1 - 581
ER -